The pharmaceutical community is excited with anticipation surrounding retatrutide, a new dual GIP and GLP-1 agonist that’s showing significant potential in clinical trials for managing obesity. Unlike some available weight loss solutions, retatrutide appears to provide a significant substantial decrease in body size and benefit metabolic health,